Martin Beck

In this discussion, Martin Beck, Senior Vice President at Boehringer Ingelheim, delves into the complexities of idiopathic and progressive pulmonary fibrosis, emphasizing its often-overlooked symptoms. He reveals insights on why many patients discontinue current treatments and shares how Boehringer's innovative AI tool, eLung, may revolutionize earlier diagnoses. Martin also introduces a new oral therapy that shows promise in improving patient adherence. The conversation sheds light on the company's commitment to tackling this fatal condition and the need for better awareness.